309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
OBJECTIVES/GOALS: Immunomodulatory drugs (IMiDs) are critical to multiple myeloma (MM) disease control. IMiDs act by inducing Cereblon-dependent degradation of IKZF1 and IKZF3, which leads to IRF4 and MYC downregulation (collectively termed the “Ikaros axis”). We therefore hypothesized that IMiD tre...
Main Authors: | Lorraine Davis, Zachary J. Walker, Denis Ohlstrom, Brett M. Stevens, Peter A. Forsberg, Tomer M. Mark, Craig T. Jordan, Daniel W. Sherbenou |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-04-01
|
Series: | Journal of Clinical and Translational Science |
Online Access: | https://www.cambridge.org/core/product/identifier/S2059866122001698/type/journal_article |
Similar Items
-
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
by: Kazuhito Suzuki, et al.
Published: (2023-11-01) -
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
by: Lorraine N. Davis, et al.
Published: (2021-04-01) -
Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
by: Marco Cippitelli, et al.
Published: (2021-01-01) -
A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
by: Katherine O. Kopp, et al.
Published: (2023-04-01) -
Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma
by: Gooding, S, et al.
Published: (2022)